REG - Belluscura PLC - Director/PDMR Shareholding

BelluscuraAnnouncement

19/07/2024 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240719:nRSS0219Xa&default-theme=true

RNS Number : 0219X  Belluscura PLC  19 July 2024

19 July 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company")

 

PDMR Award of Options

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces that the
Company has today granted unapproved share options ("Options") of 4.0 million
ordinary shares of 1 penny each in the Company ("Ordinary Shares") to Simon
Neicheril, Chief Financial Officer.

 

The Options have been awarded upon the recommendation of the Company's
Remuneration Committee.

 

The Options have an exercise price of 14.5 pence per share (being the closing
mid-market price of the Ordinary Shares on 18 July 2024) and will expire 10
years from the date of grant.

 

The Options are subject to the following performance criteria; 2.0 million
Options will vest when the price of the Ordinary Shares reaches 20p. The
further 2.0 million Options will vest when the price of the Ordinary Shares
reaches 25p.  Each Option is exercisable into one Ordinary Share.

 

Upon a change in control of the Company, or an Offer for the Company's entire
Share Capital, or termination of Mr. Neicheril's employment contract as a good
leaver, all remaining unvested Options will vest immediately.

 

 

For further information please contact:

 

 Belluscura plc                                        Tel: +44 (0)20 3128 8100
 Adam Reynolds, Chairman
 Robert Rauker, Chief Executive Officer

 SPARK Advisory Partners Limited - Nominated Adviser   Tel: +44 (0)20 3368 3550
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited - Broker                      Tel: +44 (0)20 3903 7715
 Russell Cook / Nicholas Chambers

 MHP Group - Financial PR & Investor Relations         Tel: +44 (0)20 3128 8100
 Katie Hunt / Matthew Taylor                           email: Belluscura@mhpgroup.com
                                                       (file:///C:/Users/Matthew.Taylor/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/SXDYXY87/Belluscura@mhpgroup.com)

 

About Belluscura plc (https://belluscura.com/ (https://belluscura.com/) )

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely associated ("PCA")
with them.

 

  1   Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Simon Neicheril
 2    Reason for notification
 a)   Position / status                                            Chief Financial Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Belluscura plc
 b)   LEI                                                          213800BRJQZE56XBPW94
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.01 each in Belluscura plc

      Identification code                                          ISIN: GB00BD3B8Z11
 b)   Nature of the transaction                                    Grant of Options over Ordinary shares of £0.01 each

 c)   Price(s) and volumes(s)                                      Price(s)  Volumes(s)
                                                                   14.5p     4,000,000

 

 d)   Aggregated information                                       n/a
 e)   Date of the transaction                                      19 July 2024
 f)   Place of the transaction                                     Outside a Trading Venue

 

 

 

 

 

d)

Aggregated information

n/a

e)

Date of the transaction

19 July 2024

f)

Place of the transaction

Outside a Trading Venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHRPMTTMTMBTLI